miR-375-3p inhibits the progression of laryngeal squamous cell carcinoma by targeting hepatocyte nuclear factor-1β.

hepatocyte nuclear factor-1β laryngeal squamous cell carcinoma microRNA-375-3p

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 24 03 2019
accepted: 21 05 2020
entrez: 1 9 2020
pubmed: 31 8 2020
medline: 31 8 2020
Statut: ppublish

Résumé

Laryngeal squamous cell carcinoma (LSCC) is one of the most frequently diagnosed head and neck cancers worldwide. Increasing evidence suggests that microRNAs (miRNAs/miRs) regulate the progression of tumorigenesis and the malignant behaviors of cancer cells. The aim of this study was to investigate the function and underlying mechanism of miR-375-3p in LSCC. The expression of miR-375-3p in LSCC tissues and cells was detected using reverse transcription-quantitative PCR. The effects of miR-375-3p on the malignant phenotype of LSCC cells was determined using the Cell Counting Kit-8 assay and flow cytometry. The targets of miR-375-3p were predicted using the miRDB database and confirmed by the luciferase reporter assay. The results of the present study demonstrated that miR-375-3p was downregulated in LSCC tissues and cell lines. Furthermore, overexpression of miR-375-3p significantly suppressed the proliferation and cell cycle progression of LSCC cells. Overexpression of miR-375-3p also increased LSCC cell apoptosis. Mechanistical analysis indicated that miR-375-3p bound the 3'-untranslated region of the hepatocyte nuclear factor 1β (HNF1β) and decreased its expression in LSCC cells. Consistent with the role of HNF1β in glucose metabolism, overexpression of miR-375-3p significantly inhibited glucose consumption and lactate production in LSCC cells. Transfection with HNF1β notably reversed the inhibitory effect of miR-375-3p on the proliferation of LSCC cells. Collectively, these results indicate the tumor suppressive role of miR-375-3p in LSCC via HNF1β, suggesting that miR-375-3p may serve as a potential target in the treatment of LSCC.

Identifiants

pubmed: 32863913
doi: 10.3892/ol.2020.11941
pii: OL-0-0-11941
pmc: PMC7436894
doi:

Types de publication

Journal Article

Langues

eng

Pagination

80

Informations de copyright

Copyright: © Chang et al.

Références

Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7296-7304
pubmed: 30468474
Rev Physiol Biochem Pharmacol. 2016;171:1-38
pubmed: 27457236
Cell Physiol Biochem. 2018;50(1):342-352
pubmed: 30282067
Folia Biol (Praha). 2018;64(3):71-83
pubmed: 30394265
Semin Liver Dis. 2015 Feb;35(1):3-11
pubmed: 25632930
Onco Targets Ther. 2014 Apr 05;7:525-33
pubmed: 24741319
J Cell Physiol. 2018 Aug;233(8):5574-5588
pubmed: 29521426
Annu Rev Biochem. 2010;79:351-79
pubmed: 20533884
Oral Oncol. 2015 Apr;51(4):321-31
pubmed: 25677760
J Cancer Educ. 2013 Sep;28(3):454-7
pubmed: 23728993
Mol Carcinog. 2015 Jan;54(1):35-49
pubmed: 24105991
Mayo Clin Proc. 2016 Mar;91(3):386-96
pubmed: 26944243
Int J Oncol. 2019 Feb;54(2):689-701
pubmed: 30535502
J Cell Biochem. 2018 Oct 9;:
pubmed: 30302801
Pharmacol Res. 2015 Jul;97:104-21
pubmed: 25958353
Cancer Biol Ther. 2019;20(6):826-836
pubmed: 30907227
Thorac Cancer. 2015 Jan;6(1):17-24
pubmed: 26273330
Auris Nasus Larynx. 2019 Feb;46(1):106-113
pubmed: 29843929
Pediatr Nephrol. 2016 May;31(5):707-14
pubmed: 26160100
J Pathol. 2011 Jan;223(2):102-15
pubmed: 21125669
Braz J Otorhinolaryngol. 2018 Sep - Oct;84(5):566-573
pubmed: 28823696
J Hematol Oncol. 2017 Feb 20;10(1):52
pubmed: 28219405
Biomed Pharmacother. 2014 Mar;68(2):149-54
pubmed: 24055400
Clin Otolaryngol. 2017 Feb;42(1):104-114
pubmed: 27185184
Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):629-639
pubmed: 27923456
Histopathology. 2018 Jun;72(7):1102-1114
pubmed: 29266325
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Oncotarget. 2015 Oct 13;6(31):30704-14
pubmed: 26375553
Auris Nasus Larynx. 2019 Aug;46(4):583-592
pubmed: 30454973
Int J Gynecol Cancer. 2009 Apr;19(3):471-9
pubmed: 19407577
EMBO Mol Med. 2017 Jun;9(6):852
pubmed: 28572088
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
Histol Histopathol. 2009 Nov;24(11):1479-86
pubmed: 19760597
Ann Pathol. 1999 Apr;19(2):153
pubmed: 10349487
Cancer Sci. 2010 Nov;101(11):2309-15
pubmed: 20726859
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Cell Physiol. 2019 Jul;234(7):10002-10017
pubmed: 30537109
Biochem Cell Biol. 2018 Dec;96(6):752-760
pubmed: 29874469
Oncol Lett. 2012 Dec;4(6):1151-1157
pubmed: 23226794
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Oncotarget. 2015 Sep 22;6(28):26002-17
pubmed: 26318292
Oncol Lett. 2020 Jul;20(1):774-784
pubmed: 32566004
Biochem Biophys Res Commun. 2012 Oct 19;427(2):254-60
pubmed: 22995297

Auteurs

Kunpeng Chang (K)

Department of Otolaryngology Head and Neck Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan 471000, P.R. China.

Zhenxing Wei (Z)

Department of Otolaryngology Head and Neck Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan 471000, P.R. China.

Hua Cao (H)

Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.

Classifications MeSH